Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
Recruiting
N/A
Interventional Study
Subdural Hematoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 1,000 (estimated)
- Sponsor
- University of Manitoba · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.
Trial Locations
Sorted by distance from Kentucky
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.
Exclusion Criteria:
* If informed consent cannot be obtained from the patient or their substitute decision maker.
* Known allergy to liquid embolic agent
Contacts